Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02257567
Title A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Bendamustine + Rituximab

Polatuzumab vedotin-piiq

Obinutuzumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.